AAVrh74.MHCK7.micro-Dystrophin - Nationwide Children's Hospital

Drug Profile

AAVrh74.MHCK7.micro-Dystrophin - Nationwide Children's Hospital

Alternative Names: AAVrh74.MHCK7.micro dystrophin

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Nationwide Children's Hospital; Sarepta Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy

Most Recent Events

  • 06 Nov 2017 Phase-I/II clinical trials in Duchenne muscular dystrophy (In infants, In children) in USA (IV)
  • 06 Nov 2017 The US FDA approves IND application for AAVrh74.MHCK7.micro-Dystrophin in Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top